We are live on
!
Find out more
BNP Paribas Asset Management Portfolio holdings
AUM
$86.1B
1-Year Est. Return
29.11%
This Fund
S&P 500
This Quarter
Est. Return
-2.17%
1 Year Est. Return
+29.11%
3 Year Est. Return
+87.64%
5 Year Est. Return
+102.48%
10 Year Est. Return
+408.22%
AUM
$86.1B
AUM Growth
-$1.05B
(-1.2%)
Cap. Flow
+$4.86B
Cap. Flow
% of AUM
5.64%
Top 10 Holdings %
Top 10 Hldgs %
27.63%
Holding
2,366
New
101
Increased
1,396
Reduced
686
Closed
108
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$1.43B |
| 2 |
TotalEnergies
TTE
|
+$626M |
| 3 |
Deutsche Bank
DB
|
+$326M |
| 4 |
Stellantis
STLA
|
+$263M |
| 5 |
Broadcom
AVGO
|
+$237M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ciena
CIEN
|
+$291M |
| 2 |
Apple
AAPL
|
+$262M |
| 3 |
Amazon
AMZN
|
+$219M |
| 4 |
Tesla
TSLA
|
+$205M |
| 5 |
Meta Platforms (Facebook)
META
|
+$197M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.22% |
| 2 | Healthcare | 13.97% |
| 3 | Financials | 10.51% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 8.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Aehr Test Systems
AEHR
$2.87B
| $17.1K | ﹤0.01% |
460
+94
| +26% | +$3.01K |
|
2002
Arbutus Biopharma
ABUS
$883M
| $16.9K | ﹤0.01% |
3,766
+1,367
| +57% | +$5.98K |
|
2003
Allient
ALNT
$1.51B
| $16.9K | ﹤0.01% |
286
+63
| +28% | +$3.97K |
|
2004
Vestis
VSTS
$2.06B
| $16.8K | ﹤0.01% |
2,138
+474
| +28% | +$3.46K |
|
|
CWEN.A
2005
DELISTED
Clearway Energy Class A
CWEN.A
| $16.8K | ﹤0.01% |
+429
| New | +$15.3K |
|
2006
Ibotta
IBTA
$612M
| $16.7K | ﹤0.01% |
557
+310
| +126% | +$7.25K |
|
2007
Coastal Financial
CCB
$1.09B
| $16.6K | ﹤0.01% |
218
+32
| +17% | +$2.89K |
|
2008
Liberty Live Group Series A
LLYVA
$8.74B
| $16.6K | ﹤0.01% |
181
-23
| -11% | -$2.02K |
|
2009
United States Antimony
UAMY
$817M
| $16.2K | ﹤0.01% |
+1,855
| New | +$16.2K |
|
2010
Scholastic
SCHL
$857M
| $16.2K | ﹤0.01% |
414
+108
| +35% | +$3.73K |
|
2011
Fortrea Holdings
FTRE
$1.84B
| $16K | ﹤0.01% |
1,698
+432
| +34% | +$5.55K |
|
2012
National Healthcare
NHC
$3.46B
| $16K | ﹤0.01% |
100
+12
| +14% | +$1.84K |
|
2013
Origin Bancorp
OBK
$1.62B
| $16K | ﹤0.01% |
385
+120
| +45% | +$5K |
|
2014
Heritage Financial
HFWA
$1.25B
| $15.9K | ﹤0.01% |
611
+184
| +43% | +$4.78K |
|
2015
LeMaitre Vascular
LMAT
$2.23B
| $15.7K | ﹤0.01% |
144
-25
| -15% | -$2.38K |
|
|
PENG
2016
Penguin Solutions Inc
PENG
$2.99B
| $15.7K | ﹤0.01% |
890
+181
| +26% | +$3.44K |
|
2017
Gorman-Rupp
GRC
$2.1B
| $15.7K | ﹤0.01% |
252
+26
| +12% | +$1.54K |
|
2018
Myriad Genetics
MYGN
$538M
| $15.5K | ﹤0.01% |
3,437
+1,577
| +85% | +$8.22K |
|
2019
Daktronics
DAKT
$957M
| $15.3K | ﹤0.01% |
784
+189
| +32% | +$4.31K |
|
2020
Kforce
KFRC
$1.01B
| $15.3K | ﹤0.01% |
522
+178
| +52% | +$5.41K |
|
2021
Teladoc Health
TDOC
$1.56B
| $15.1K | ﹤0.01% |
2,774
+396
| +17% | +$2.22K |
|
2022
Beazer Homes USA
BZH
$896M
| $15.1K | ﹤0.01% |
785
+111
| +16% | +$2.56K |
|
2023
Iovance Biotherapeutics
IOVA
$2.29B
| $15.1K | ﹤0.01% |
4,298
+1,102
| +34% | +$3.52K |
|
2024
Interparfums
IPAR
$3.84B
| $15.1K | ﹤0.01% |
166
+43
| +35% | +$4.08K |
|
2025
Integra LifeSciences
IART
$1.44B
| $15K | ﹤0.01% |
1,596
+415
| +35% | +$4.56K |
|
Similar funds
BNP Paribas Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, BNP Paribas Asset Management held 2,366 positions worth $86.1B, down 1.2% from $87.2B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
BNP Paribas Asset Management deployed $4.86B of net new capital in Q1 2026, opening 101 new positions and adding to 1,396 existing holdings. Its largest new stake was Viking Holdings: 1,864,036 shares worth $137M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 37% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Ciena, an estimated $291M trimmed.
- BNP Paribas Asset Management's largest Q1 2026 buy was Viking Holdings: 1,864,036 shares worth $137M.
- BNP Paribas Asset Management added most to AstraZeneca in Q1 2026, an estimated $1.43B increase.
- BNP Paribas Asset Management's biggest Q1 2026 reduction was Ciena, cutting an estimated $291M.
- BNP Paribas Asset Management fully exited Exact Sciences in Q1 2026, selling an estimated $35.9M.
- BNP Paribas Asset Management's ten largest holdings make up 28% of its $86.1B portfolio in Q1 2026.
- BNP Paribas Asset Management opened 101 new positions and closed 108 in Q1 2026.
- BNP Paribas Asset Management's portfolio value fell 1.2% quarter-over-quarter to $86.1B.
Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.